Zobrazeno 1 - 10
of 244
pro vyhledávání: '"C R, Wolf"'
Autor:
M M Schmitgen, J Horvath, C Mundinger, D N Wolf, F Sambataro, D Hirjak, M K Kubera, J Koenig, C R Wolf
Publikováno v:
Suchttherapie.
Publikováno v:
Drug Metabolism and Disposition
Cytochrome P450s CYP1A1 and CYP1A2 can metabolize a broad range of foreign compounds and drugs. However, these enzymes have significantly overlapping substrate specificities. To establish their relative contribution to drug metabolism in vivo, we use
Autor:
C J, Henderson, Y, Kapelyukh, N, Scheer, A, Rode, A W, McLaren, A K, MacLeod, D, Lin, J, Wright, L A, Stanley, C R, Wolf
Publikováno v:
Drug Metabolism and Disposition
Species differences in drug metabolism and disposition can confound the extrapolation of in vivo PK data to man and also profoundly compromise drug efficacy studies owing to differences in pharmacokinetics, in metabolites produced (which are often ph
Autor:
Gillian Smith, E. B. Amankwatia, Alastair J. Munro, S. Weidlich, Robert Steele, Probir Chakravarty, C R Wolf, F A Carey
Publikováno v:
British Journal of Cancer
Background: Colorectal cancers arise from benign adenomas, although not all adenomas progress to cancer and there are marked interpatient differences in disease progression. We have previously associated KRAS mutations with disease progression and re
Genetically humanized mice for proteins involved in drug metabolism and toxicity and mice engrafted with human hepatocytes are emerging as promising in vivo models for improved prediction of the pharmacokinetic, drug–drug interaction, and safety ch
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4afb86886e2d155adcdbad54f49e1532
https://doi.org/10.1016/b978-0-12-409547-2.12376-5
https://doi.org/10.1016/b978-0-12-409547-2.12376-5
Autor:
Michelle Ferguson, C R Wolf, Gillian Smith, H C Young, Lynne Sawers, Probir Chakravarty, B R Ihrig
Publikováno v:
British Journal of Cancer
Background: Chemotherapy response in ovarian cancer patients is frequently compromised by drug resistance, possibly due to altered drug metabolism. Platinum drugs are metabolised by glutathione S-transferase P1 (GSTP1), which is abundantly, but varia
Autor:
Gillian Smith, Charlie Gourley, M. T. H. Ng, Michelle Ferguson, C R Wolf, L. Shepherd, C.S. Herrington
Publikováno v:
British Journal of Cancer
Smith, G, Ng, M T H, Shepherd, L, Herrington, C S, Gourley, C, Ferguson, M J & Wolf, C R 2012, ' Individuality in FGF1 expression significantly influences platinum resistance and progression-free survival in ovarian cancer ', British Journal of Cancer, vol. 107, no. 8, pp. 1327-36 . https://doi.org/10.1038/bjc.2012.410
Smith, G, Ng, M T H, Shepherd, L, Herrington, C S, Gourley, C, Ferguson, M J & Wolf, C R 2012, ' Individuality in FGF1 expression significantly influences platinum resistance and progression-free survival in ovarian cancer ', British Journal of Cancer, vol. 107, no. 8, pp. 1327-36 . https://doi.org/10.1038/bjc.2012.410
BACKGROUND: Ovarian cancer is frequently advanced at presentation when treatment is rarely curative. Response to first-line platinum-based chemotherapy significantly influences survival, but clinical response is unpredictable and is frequently limite
Autor:
Maria João Gama, A. Neves Carvalho, Margarida Castro-Caldas, C.M.P. Rodrigues, C. R. Wolf, Elsa Rodrigues, Colin J. Henderson
Publikováno v:
Molecular Neurobiology. 46:475-486
Mitochondrial dysfunction and oxidative stress are implicated in the neurodegenerative process in Parkinson's disease (PD). Moreover, c-Jun N-terminal kinase (JNK) plays an important role in dopaminergic neuronal death in substantia nigra pars compac
Autor:
Michael E. Burczynski, F A Carey, G Miele, G Feuerstein, K Walsh, S. Weidlich, C R Wolf, Daniel Crowther, Robert Steele, Gillian Smith
Publikováno v:
British Journal of Cancer
Background: The epidermal growth factor receptor-targeted monoclonal antibody cetuximab (Erbitux) was recently introduced for the treatment of metastatic colorectal cancer. Treatment response is dependent on Kirsten-Ras (K-Ras) mutation status, in wh
Publikováno v:
British Journal of Cancer
Background: Response to EGFR-targeted therapies in colorectal cancer patients has been convincingly associated with Kirsten-Ras (K-Ras) mutation status. Current mandatory mutation testing for patient selection is limited to the K-Ras ‘hotspot' codo